Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GPCR
#1638
Structure Therapeutics Inc - American Depositary Shares
47.3
7
USD
-0.04%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-3.76%
Monthly Change
+0.17%
6 month change
-23.60%
Year Change
+77.15%
Previous Close
49.2
2
Open
47.3
7
Low
47.3
7
High
47.3
7
Volume
27
Markets
US Stock Market
Healthcare
Biotechnology
GPCR
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2023
2024
2025
Total assets
482.02 M
903.33 M
1.58 B
Total liabilities
29.05 M
38.49 M
67.54 M
Total equity
452.97 M
864.84 M
1.52 B
Total liabilities & shareholders' equities
482.02 M
903.33 M
1.58 B
Total debt
—
—
—
Net debt
—
—
—
News
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term (SEPN)
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
Structure Therapeutics - A Strong Bet For An Oral GLP-1 Approval Before 2030 (NASDAQ:GPCR)
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
The BioRevolution Has Accelerated
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?